Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study Meeting Abstract

  

Authors:	Stein, E. M.; Dinardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I.; Kantarjian, H. M.; Collins, R.; Patel, M. R.; Stein, A. S.; Sekeres, M. A.; Swords, R. T.; Medeiros, B. C.; Knight, R. D.; Agresta, S. V.; de Botton, S.; Tallman, M. S.
Abstract Title:	Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study
Meeting Title:	53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	15 Suppl.
Meeting Dates:	2017 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-05-20
Start Page:	374s
Language:	English
ACCESSION:	WOS:000411931708034
DOI:	10.1200/JCO.2017.35.15_suppl.7004
PROVIDER:	wos
Notes:	Meeting Abstract: 7004 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147275